ADAR1 Capital Management LLC Purchases New Position in Inhibikase Therapeutics, Inc. (NYSE:IKT)

ADAR1 Capital Management LLC acquired a new stake in Inhibikase Therapeutics, Inc. (NYSE:IKT - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 5,103,005 shares of the company's stock, valued at approximately $16,585,000. Inhibikase Therapeutics makes up approximately 3.3% of ADAR1 Capital Management LLC's portfolio, making the stock its 8th largest holding. ADAR1 Capital Management LLC owned 7.36% of Inhibikase Therapeutics at the end of the most recent quarter.

Separately, Blair William & Co. IL raised its position in Inhibikase Therapeutics by 7.0% during the fourth quarter. Blair William & Co. IL now owns 134,953 shares of the company's stock worth $439,000 after acquiring an additional 8,833 shares in the last quarter. 3.81% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a "neutral" rating on shares of Inhibikase Therapeutics in a research report on Friday, March 28th.

Inhibikase Therapeutics Trading Up 11.3 %

NYSE:IKT traded up $0.21 on Friday, hitting $2.07. The company's stock had a trading volume of 105,774 shares, compared to its average volume of 228,247. Inhibikase Therapeutics, Inc. has a one year low of $1.12 and a one year high of $4.20. The stock has a fifty day moving average of $2.26 and a two-hundred day moving average of $2.44. The firm has a market capitalization of $153.89 million, a P/E ratio of -0.78 and a beta of 1.02.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract.